Background and aims: This retrospective review of patients with recurrent
most frequently bevacizumab/carboplatin (7/47; 14.9%). Thirteen patients (18%) experienced a grade 3 AE of special interest for bevacizumab.
Conclusions: Treatment patterns and outcomes for patients with recurrent glioblastoma receiving bevacizumab in a real-world setting were comparable with those reported in prospective clinical trials.
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| INTRODUCTION
Glioblastomas are the most common and most aggressive form of primary brain tumors in adults. 1 Patients with glioblastoma have a very poor prognosis because of the high propensity for relapse, 2 with reported median survival times for patients with recurrent disease of just 3 to 9 months. 3, 4 The angiogenic factor vascular endothelial growth factor (VEGF) is expressed at high levels in glioblastoma relative to other cancer types 4 ; thus, inhibitors of VEGF have been investigated for the treatment of glioblastoma. 5 In 2009, the anti-VEGF monoclonal antibody bevacizumab received accelerated United States Food and Drug Administration (FDA) approval as a single agent for the treatment of recurrent glioblastoma. 6 Approval of bevacizumab was based on durable objective response rates (ORRs) and 6-month progression-free survival (PFS) data obtained from two single-arm phase 2 studies.
The first study evaluated the activity of bevacizumab monotherapy followed by bevacizumab plus irinotecan at disease progression (PD). The 6-month PFS rate was 29.0%, median overall survival (OS) was 31 weeks, and radiographic response was recorded in 71% and 35% of patients, based on Levin and Macdonald criteria, respectively. 7 A companion study assessed the efficacy of bevacizumab alone and in combination with irinotecan following PD. In the bevacizumab monotherapy arm, the 6-month PFS rate was 42.6%, median OS was 9.2 months, and the ORR was 28.2%. 8 Grade 3/4 adverse events (AEs) across the two studies were mostly nonhematologic and included hypertension and thromboembolic events. 7, 8 Patients enrolled in randomized clinical trials do not always reflect real-world populations. 
| Statistical analysis
Categorical variables were described with frequency distributions, two-sided tests were performed, and the SAS software, version 9.4
(SAS Institute), was used for all the analyses. The Kaplan-Meier estimator was used to describe OS, PFS, and time to greater than or equal to 20% reduction in KPS. The Cox proportional hazards model was used to assess the effect of patient baseline demographic and clinical factors on OS and PFS. Safety was summarized using the maximum NCI-CTCAE grade experienced for each type of AE. 
| Initial bevacizumab-containing treatment regimens
The median time between diagnosis of glioblastoma and initiation of bevacizumab treatment was 9 months (range, 
| Survival
The median duration of follow-up at the time of data cut off was Figure 1C ).
| Performance status
Of the 61 patients with a baseline KPS available within 2 months prior to starting bevacizumab and at least one follow-up KPS assessment, 17 patients (27.9%) experienced a greater than or equal to 20% reduction in KPS from bevacizumab initiation ( Figure 2 ). The median time to greater than or equal to 20% reduction in KPS from bevacizumab initiation was 29.3 months (95% CI, 13.8-∞), and the proportion of patients without a KPS reduction of greater than or equal to 20% from bevacizumab initiation was 77.4%, 51.8%, and 41.4% at 12, 24, and 36 months, respectively.
| Corticosteroid use during bevacizumab treatment
Overall, 31/74 patients (41.9%) were receiving corticosteroids at the time of bevacizumab initiation. Of these, 17 patients (54.8%) discontinued corticosteroids during bevacizumab therapy and one patient (3.2%) discontinued corticosteroids while not receiving (P = 0.0382, log-rank). Corresponding median PFS values were 8.6 months (95% CI, 4.6-9.7) and 3.7 months (95% CI, 2.7-6.6), respectively (P = 0.0243, log-rank).
| Safety
AEs reported at a cumulative incidence of greater than or equal to 10% across all grades during bevacizumab therapy (including salvage bevacizumab treatment) are displayed in Table 3 . However, assessment of attribution to bevacizumab or other therapy was not com- bronchopulmonary hemorrhage (n = 1), hypertension (n = 7, 9%), and thromboembolic event (n = 3, 4%). There were no grade 4 AESIs.
| Patterns of treatment until bevacizumab failure
Treatment failure after initial bevacizumab occurred in 70 patients.
Sixty of these patients (85.7%) received bevacizumab-based therapy until failure, including 55 patients (78.6%) who had PD and five patients (7.1%) who died ( Figure 3 and Table S1 ). Nine of the 70 patients (12.9%)
were off all therapy at the time of failure. Six of these patients stopped the bevacizumab-based regimen because of AEs, two patients had intercurrent illnesses, and one patient refused further treatment. One of the 70 patients (1.4%) received bevacizumab-based therapy followed by nonbevacizumab therapy prior to failure.
After initial bevacizumab treatment failure, 47 patients received salvage therapy (Table S2) . Overall, 41 of the 47 patients (87.2%) received a bevacizumab-based regimen as their first salvage regimen; 38 of these 41 patients remained on a bevacizumab-based regimen until they died. The most frequently prescribed first salvage regimens were bevacizumab/carboplatin (7/47, 14.9%) and bevacizumab/irinotecan and bevacizumab/metronomic temozolomide (5/47, 10.6% each).
| DISCUSSION
Because of the heterogeneous nature of glioblastoma, there is currently no standard treatment for patients with recurrent disease.
2 bevacizumab. 12 It is noteworthy that our patients were initiated on treatment before the publication of the BELOB trial, 13 and thus, the prescribed regimen would most probably be different if the analyses were repeated today. No specific patient baseline or disease characteristics were associated with the improved survival outcomes seen in the analysis by Chen and colleagues. 15 However, we observed prolonged OS and PFS in patients who did not require corticosteroids at the start of bevacizumab therapy, as reported previously in pooled analyses of patients with recurrent glioblastoma enrolled in clinical trials. 17, 18 No statistically significant difference in median OS bev was observed for patients receiving bevacizumab at first versus later recurrence, which is in agreement with previously published data for patients with recurrent glioblastoma treated in clinical practice stating that timing of bevacizumab treatment does not impact survival. 19 This is also likely to be impacted by the fact that patients needing bevacizumab at first recurrence are those with a larger tumor or a more rapid disease progression than patients who initiate it later in their disease course.
Results of a large population-based Surveillance, Epidemiology, and End Results (SEER) analysis demonstrated improved OS in ( Bevacizumab was well tolerated in our study, with decreased white blood cell count, fatigue and decreased neutrophil count being the most frequently reported grade 3/4 AEs. AESIs for bevacizumab such as hypertension (9%) and thromboembolic events (4%) were reported at a similar rate to the pivotal phase 2 clinical studies of bevacizumab. 7, 8 Our study is limited by its retrospective nature, the inclusion of patients from only a single center, and the lack of data on the molecular genetics of the tumors. The wide variety of bevacizumabcontaining regimens received by the patients, and the fact that patient-specific treatment was not mandated by a study protocol, also limit the findings. However, in terms of survival, corticosteroid usage, and baseline KPS, our results compare favorably with those published in prospective clinical trials, which may not always accurately reflect real-world populations.
Taken together, these data indicate an important role for bevacizumab as part of the treatment modality for recurrent glioblastoma. Bevacizumab-based regimens were the most commonly used regimens both prior to, and following, first bevacizumab failure. Patient outcomes in this real-world setting were comparable with those reported in prospective clinical trials, and bevacizumab was generally well tolerated.
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